StockData
Nexentis Technologies Inc. logo

Nexentis Technologies Inc. (NXTS) company profile

NXTSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$1.82−0.17 (-8.42%)

Close on Nov 17, 2026Market cap $2.65MP/E –Yield –

About Nexentis Technologies

Pharmaceutical Preparations, SIC 2834

Nexentis Technologies, Inc. is a corporate entity engaged in biotechnology activities and renewable energy projects. Through its operating segments, the company participates in agricultural and life science ventures, including collaborations and investments associated with Save Foods Ltd., Plantify Foods, and MitoCareX Bio Ltd. Additionally, the business focuses on clean energy initiatives through solar photovoltaic joint ventures and partnership arrangements involving Solterra Renewable Energy Ltd., serving commercial, technological, and agricultural markets.

The company maintains operational activities and jurisdictional interests across Israel, the United States, and Italy. Its primary executive offices and headquarters are located at Pinhas Sapir St. 3, Kiryat HaMada, Ness Ziona 7403626, Israel. Nexentis Technologies also holds active partnership agreements, commercial arrangements, and facility leases across these international operating regions.

Summary of the business section of Nexentis Technologies's latest annual report, written by StockData.

Company profile

Company

Legal name
Nexentis Technologies Inc.
Founded
2009
Headquarters
New York, NY
Address
156 Fifth Avenue 10th Floor, Co Earthbound Llc 10010-7751
Phone
972544561349
Employees
7, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Nevada
Fiscal year ends
December 31
Auditor
Somekh Chaikin, Tel Aviv, Israel

Stock & identifiers

Ticker
NXTS
Former tickers
NITO until Feb 26, 2026; SVFD until Mar 19, 2024
Exchange
Nasdaq
IPO date
May 17, 2021
Shares outstanding
1M, Aug 13, 2026
Public float
$6.39M, Jun 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-7 reverse, Apr 8, 2026; 1-for-35 reverse, Sep 22, 2025; 1-for-6.67 reverse, Nov 14, 2023; 1-for-7 reverse, Oct 6, 2023; 1-for-7 reverse, Feb 25, 2021; 1-for-15 reverse, Jun 13, 2019
SEC CIK
1789192
CUSIP
80512Q600
ISIN
US80512Q6008
FIGI
BBG000PZ6S24
Share class FIGI
BBG001T659H9
EIN
26-4684680

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
David PalachChief Executive Officer540,000
Shlomo ZakaiController82,478
Lital BardaChief Financial Officer263,055
Udi Ovadia KalifiDirector72,389
Asaf ItzhaikDirector65,000
Amitay WeissDirector570,000
Liat SidiDirector65,000
Ronen RosenbloomDirector84,140
Israel Yakov BerensteinDirector84,140
Eliahou ArbibDirector84,140

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
May 17, 2021
Offer price
$11.00
Securities offered
1,090,909
Gross proceeds
$12.00M
Exchange
Nasdaq
Lock-up ends (est.)
Nov 13, 2021

“Per Share Total Initial public offering price $ 11.00 $ 12,000,000 Underwriting discounts and commissions (1) $ 0.77 $ 840,000 Proceeds, before expenses, to us $ 10.23 $ 11,160,000 (1) Underwriting discounts and commissions do not include a non-accountable expense allowance equal to 1.0% of the initial public offer”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 31, 2026, we, together with our wholly owned subsidiary, MitoCareX, have seven full-time employees and two part time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?